Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Vistagen Therapeutics (VTGN) Leases (2019 - 2025)

Vistagen Therapeutics' Leases history spans 6 years, with the latest figure at $939000.0 for Q4 2025.

  • For Q4 2025, Leases fell 35.73% year-over-year to $939000.0; the TTM value through Dec 2025 reached $939000.0, down 35.73%, while the annual FY2025 figure was $1.3 million, 26.65% down from the prior year.
  • Leases for Q4 2025 was $939000.0 at Vistagen Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Leases topped out at $3.2 million in Q1 2021 and bottomed at $14700.0 in Q2 2021.
  • The 4-year median for Leases is $1.7 million (2024), against an average of $1.8 million.
  • The largest YoY upside for Leases was 20506.12% in 2021 against a maximum downside of 99.58% in 2021.
  • A 4-year view of Leases shows it stood at $2.8 million in 2021, then fell by 29.86% to $1.9 million in 2023, then dropped by 24.44% to $1.5 million in 2024, then crashed by 35.73% to $939000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Leases are $939000.0 (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).